Tandem Diabetes Care shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $21 to $45.
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care's stock (TNDM) experienced a price increase following an upgrade by Wells Fargo from Equal-Weight to Overweight, with a new price target set at $45, up from $21.
April 29, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tandem Diabetes Care's stock received a significant upgrade from Wells Fargo, moving from Equal-Weight to Overweight, with a price target increase from $21 to $45.
The upgrade by a major financial institution like Wells Fargo typically signals a strong bullish outlook on the stock, suggesting confidence in the company's future performance. The substantial increase in the price target reflects an expectation of significant stock appreciation, likely influencing investor sentiment and potentially driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100